Drugs / CD19 CAR.p40-T
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07584889 | Apr 2024 → Apr 2029 expected | B-cell neoplasm, acute lymphoblastic leukemia, acute myeloid leukemia | Shenzhen University General Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07097207 | Oct 2023 → Sep 2026 overdue | B-cell non-Hodgkin lymphoma | Shenzhen University General Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19 CAR.p40-T | “Eligible subjects (n=20) will be assigned by the investigator to receive either CD19CD20 CAR.p40-T injection or CD19 CAR.p40-T injection.” NCT07097207 ↗1“CD19-CAR.p40-T is a genetically modified autologous T-cell product designed to target CD19-positive malignant cells” NCT07584889 ↗ |
| Modality | Cell therapy | “CD19-CAR.p40-T is a genetically modified autologous T-cell product designed to target CD19-positive malignant cells” NCT07584889 ↗ |
| Route | Intravenous | “CD19-CAR.p40-T cells will then be administered as a single intravenous infusion” NCT07584889 ↗ |
| Target | CD19 | “designed to target CD19-positive malignant cells” NCT07584889 ↗ |